keyword
https://read.qxmd.com/read/38645660/the-active-ingredient-catalpol-in-rehmannia-glutinosa-reduces-blood-glucose-in-diabetic-rats-via-the-ampk-pathway
#1
JOURNAL ARTICLE
Yang Li, Qiang Chen, Hong-Juan Sun, Jian-Hong Zhang, Xuan Liu
BACKGROUND: Type 2 diabetes mellitus (T2DM) poses a huge threat to population health globally, and more drugs need to be explored for treatment. In this study, we investigated the mechanism of active ingredient catalpol in Rehmannia glutinosa on reduces blood glucose in diabetic. METHODS: The T2DM model was constructed by intraperitoneal injection of streptozotocin into Sprague-Dawley (SD) rats, which were randomly grouped into diabetes model group, pioglitazone group, Rehmannia glutinosa group, catalpol high-dose group, catalpol low-dose group and normal control group...
2024: Diabetes, Metabolic Syndrome and Obesity
https://read.qxmd.com/read/38634079/effects-of-antidiabetic-drugs-on-bone-metabolism
#2
JOURNAL ARTICLE
Nuria Padilla Apuntate, Carmen G Puerto Cabeza, Alba Gallego Royo, Nuria Goñi Ros, Claudia Abadía Molina, Javier Acha Pérez, Pilar Calmarza
OBJECTIVES: The prevalence of diabetes mellitus type 2 (DMT2) is increasing exponentially worldwide. DMT2 patients have been found to be at a higher risk for bone fractures than the healthy population. Hence, improving our understanding of the impact of antidiabetic drugs on bone metabolism is crucial. METHODS: A descriptive, retrospective study involving 106 patients receiving six groups of antidiabetic drugs: insulin; dipeptidylpeptidase four inhibitors (DPP4i); glucagon-like peptide type 1 receptor agonists (GLP1ra); sulfonylureas; sodium-glucose cotransporter two inhibitors (SGLT2i); and pioglitazone, in which osteocalcin (OC), bone alkaline phosphatase (BAP) and C-terminal telopeptide of collagen type 1 or beta-crosslaps (β-CTx) were determined...
March 2024: Adv Lab Med
https://read.qxmd.com/read/38630788/afriplex-grttm-extract-attenuates-hepatic-steatosis-in-an-in-vitro-model-of-nafld
#3
JOURNAL ARTICLE
Kwazi Gabuza, Thendo I Mabuda, Oelfah Patel, Noxolo Khuboni, Ruzayda van Aarde, Sylvia Riedel, Nonhlakanipho F Sangweni, Shantal Windvogel, Rabia Johnson, Christo J F Muller
BACKGROUND: Currently, it is acknowledged that vitamin E, insulin sensitizers and anti-diabetic drugs are used to manage non-alcoholic fatty liver disease (NAFLD), however, these therapeutic interventions harbour adverse side effects. Pioglitazone, an anti-diabetic drug, is currently the most effective therapy to manage NAFLD. The use of natural medicines is widely embraced due to the lack of evidence of their negative side effects. Rooibos has been previously shown to decrease inflammation and oxidative stress in experimental models of diabetes, however, this is yet to be explored in a setting of NAFLD...
2024: PloS One
https://read.qxmd.com/read/38629099/effects-of-crocus-sativus-and-its-constituent-safranal-and-pioglitazone-on-systemic-inflammation-and-oxidative-stress-induced-by-paraquat-aerosol-in-rats
#4
JOURNAL ARTICLE
Arghavan Memarzia, Seydeh Zahra Ghasemi, Fatemeh Amin, Zahra Gholamnezhad, Mohammad Hossein Boskabady
OBJECTIVES: The effects of Crocus sativus , safranal, and pioglitazone on aerosolized paraquat (PQ)-induced systemic changes were examined. MATERIALS AND METHODS: Control (Ctrl) and PQ groups of rats were exposed to saline or PQ (27 and 54 mg/m3, PQ-L and PQ-H) aerosols eight times on alternate days. Nine PQ-H groups were treated with dexamethasone (0.03 mg/kg/day, Dexa), two doses of C. sativus extract (20 and 80 mg/kg/day, CS-L and CS-H), safranal (0.8 and 3.2 mg/kg/day, Saf-L and Saf-H), pioglitazone (5 and 10 mg/kg/day, Pio-L and Pio-H), and the combination of low dose of the pioglitazone and extract or safranal (Pio + CS and Pio + Saf) after the end of PQ exposure...
2024: Iranian Journal of Basic Medical Sciences
https://read.qxmd.com/read/38627972/efficacy-of-pharmacologic-interventions-on-magnetic-resonance-imaging-biomarkers-in-patients-with-nonalcoholic-fatty-liver-disease-systematic-review-and-network-meta-analysis
#5
REVIEW
Konstantinos Malandris, Stylianos Papandreou, Despoina Vasilakou, Panagiota Kakotrichi, Anna Sarakapina, Georgios Kalopitas, Thomas Karagiannis, Olga Giouleme, Eleni Bekiari, Aris Liakos, Fotini Iatridi, Paschalis Paschos, Emmanouil Sinakos, Apostolos Tsapas
BACKGROUND AND AIM: Several agents are under investigation for nonalcoholic fatty liver disease (NAFLD). We assessed the comparative efficacy of pharmacologic interventions for patients with NAFLD focusing on magnetic resonance imaging (MRI) biomarkers. METHODS: We searched Medline, Embase, and CENTRAL. We included randomized controlled trials of more than 12 weeks of intervention that recruited patients with biopsy-confirmed or MRI-confirmed NAFLD and assessed the efficacy of interventions on liver fat content (LFC) and fibrosis by means of MRI...
April 16, 2024: Journal of Gastroenterology and Hepatology
https://read.qxmd.com/read/38607518/pioglitazone-ameliorates-ischemia-reperfusion-induced-acute-kidney-injury-via-oxidative-stress-attenuation-and-nlrp3-inflammasome
#6
JOURNAL ARTICLE
Zhenfeng Ye, Jing Zhang, Zhou Xu, Zhangwang Li, Gaomin Huang, Bin Tong, Panpan Xia, Yunfeng Shen, Honglin Hu, Peng Yu, Xiaoqing Xi
Acute kidney injury (AKI) induced by renal ischemia/reperfusion injury (IRI) is a severe clinical condition. ROS accumulation, antioxidant pathways deficiency, and inflammation are involved in IRI. Pioglitazone (Pio) exerts anti-inflammatory and antioxidant effects. The aim of this study was to explore the protective effects of pioglitazone against IRI-induced AKI. Pathogen-free Sprague-Dawley (SD) rats were arbitrarily divided into four groups: Sham operation group Control (CON) group, CON + Pio group, I/R + Saline group, and I/R + Pio group...
April 12, 2024: Human Cell
https://read.qxmd.com/read/38601974/pioglitazone-enhances-cisplatin-s-impact-on-triple-negative-breast-cancer-role-of-ppar%C3%AE-in-cell-apoptosis
#7
JOURNAL ARTICLE
Qamraa Hamad Alqahtani, Layla Abdullah Alkharashi, Hanaa Alajami, Ishraq Alkharashi, Layan Alkharashi, Shoug Nasser Alhinti
Peroxisome proliferator-activated receptor-gamma (PPARγ) has been recently shown to play a role in many cancers. The breast tissue of triple-negative breast cancer (TNBC) patients were found to have a significantly lower expression of PPARγ than the other subtypes. Furthermore, PPARγ activation was found to exert anti-tumor effects by inhibiting cell proliferation, differentiation, cell growth, cell cycle, and inducing apoptosis. To start with, we performed a bioinformatic analysis of data from OncoDB, which showed a lower expression pattern of PPARγ in different cancer types...
May 2024: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://read.qxmd.com/read/38597373/loss-of-gcn5l1-exacerbates-damage-in-alcoholic-liver-disease-through-ferroptosis-activation
#8
JOURNAL ARTICLE
Chenxi Yang, Ye Yang, Xiuya Hu, Qiqi Tang, Jiaqi Zhang, Peiyu Zhang, Xin Lu, Juan Xu, Sai Li, Zhengni Dong, Lu Zhu, Lingdi Wang
BACKGROUND AND AIMS: Iron overload, oxidative stress and ferroptosis are associated with liver injury in alcohol-associated liver disease (ALD), however, the crosstalk among these regulatory pathways in ALD development is unclear. METHODS: ALD mouse model and general control of amino acid synthesis 5 like 1 (GCN5L1) liver knockout mice were generated to investigate the role of GCN5L1 in ALD development. Proteomic screening tests were performed to identify the key factors mediating GCN5L1 loss-induced ALD...
April 10, 2024: Liver International: Official Journal of the International Association for the Study of the Liver
https://read.qxmd.com/read/38584180/risk-of-diabetic-retinopathy-and-diabetic-macular-oedema-with-sodium-glucose-cotransporter-2-inhibitors-and-glucagon-like-peptide-1-receptor-agonists-in-type-2-diabetes-a-real-world-data-study-from-a-global-federated-database
#9
JOURNAL ARTICLE
Aikaterini Eleftheriadou, David Riley, Sizheng S Zhao, Philip Austin, Gema Hernández, Gregory Y H Lip, Timothy L Jackson, John P H Wilding, Uazman Alam
AIMS/HYPOTHESIS: A protective role of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP1-ra) in the development of diabetic retinopathy and diabetic macular oedema has been described in some recent studies, which may extend beyond glycaemic control. We aimed to review the clinical impact of SGLT2i and GLP1-ra therapy on the risk of diabetic retinopathy and diabetic macular oedema in individuals with type 2 diabetes taking insulin. METHODS: This is a retrospective cohort analysis of approximately two million people with type 2 diabetes receiving insulin across 97 healthcare organisations using a global federated health research network (TriNetX, Cambridge, USA)...
April 8, 2024: Diabetologia
https://read.qxmd.com/read/38563599/a-pioglitazone-nanoformulation-designed-for-cancer-associated-fibroblast-reprogramming-and-cancer-treatment
#10
JOURNAL ARTICLE
Shevanuja Theivendran, He Xian, Jingjing Qu, Yaping Song, Bing Sun, Hao Song, Chengzhong Yu
The recent focus of cancer therapeutics research revolves around modulating the immunosuppressive tumor microenvironment (TME) to enhance efficacy. The tumor stroma, primarily composed of cancer-associated fibroblasts (CAFs), poses significant obstacles to therapeutic penetration, influencing resistance and tumor progression. Reprogramming CAFs into an inactivated state has emerged as a promising strategy, necessitating innovative approaches. This study pioneers the design of a nanoformulation using pioglitazone, a Food and Drug Administration-approved anti-diabetic drug, to reprogram CAFs in the breast cancer TME...
April 2, 2024: Nano Letters
https://read.qxmd.com/read/38563125/ppar-gamma-agonistic-activity-of-dillapiole-protective-effects-against-diabetic-nephropathy
#11
JOURNAL ARTICLE
Sana Shafi, Navneet Khurana, Jeena Gupta
Using structural similarity approach we identified dillapiole, a phenylpropanoid, the main component of Piper aduncum L. and Anethum graveolens L. essential oils as potential PPARγ agonist. Molecular docking revealed that dillapiole binds to the active site of PPARγ, similar to pioglitazone binding. In silico ADME studies showed that dillapiole has high water solubility and GI absorption. Dillapiole was also observed to be partial agonist of PPARγ receptors with EC50 of 43.95 µM...
April 2, 2024: Natural Product Research
https://read.qxmd.com/read/38563070/assessment-of-cyp-mediated-drug-interactions-for-enasidenib-based-on-a-cocktail-study-in-patients-with-relapse-or-refractory-acute-myeloid-leukemia-or-myelodysplastic-syndrome
#12
JOURNAL ARTICLE
Yiming Cheng, Xiaomin Wang, Atalanta Ghosh, Jie Pu, Leonidas N Carayannopoulos, Yan Li
As a selective and potent inhibitor targeting the isocitrate dehydrogenase-2 (IDH2) mutant protein, enasidenib obtained approval from the US Food and Drug Administration (FDA) in 2017 for adult patients with acute myeloid leukemia (AML) with an IDH2 mutation. In vitro investigations demonstrated that enasidenib affects various drug metabolic enzymes and transporters. This current investigation aimed to assess enasidenib on the pharmacokinetics (PKs) of CYP substrates, including dextromethorphan (CYP2D6 probe drug), flurbiprofen (CYP2C9 probe drug), midazolam (CYP3A4 probe drug), omeprazole (CYP2C19 probe drug), and pioglitazone (CYP2C8 probe drug), in patients with AML or myelodysplastic syndrome...
April 2, 2024: Journal of Clinical Pharmacology
https://read.qxmd.com/read/38558280/effect-of-combination-pioglitazone-with-sodium-glucose-cotransporter-2-inhibitors-or-glucagon-like-peptide-1-receptor-agonists-on-outcomes-in-type-2-diabetes-a-systematic-review-meta-analysis-and-real-world-study-from-an-international-federated-database
#13
JOURNAL ARTICLE
Matthew Anson, Alex E Henney, Sizheng S Zhao, Gema H Ibarburu, Gregory Y H Lip, Daniel J Cuthbertson, Katarzyna Nabrdalik, Uazman Alam
AIMS: To evaluate the efficacy and cardiovascular outcomes of combination pioglitazone with either a glucagon-like peptide-1 receptor agonist (GLP-1RA) or a sodium-glucose cotransporter-2 (SGLT2) inhibitor in individuals with type 2 diabetes (T2D) by conducting a systematic review, meta-analysis, and analysis of a large international real-world database. METHODS: We searched MEDLINE, SCOPUS and Web of Science to identify relevant articles for inclusion (PROSPERO [CRD: 42023483126])...
April 1, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38547520/chronotropic-responses-to-glp-1-receptor-agonists-and-sitagliptin-in-atria-from-diabetic-rats
#14
JOURNAL ARTICLE
Esra Akcabag, Zinnet Sevval Aksoyalp, Feride Oner, Zeliha Bayram, Gul Ozbey, Cahit Nacitarhan, Sebahat Ozdem, Arda Tasatargil, Sadi S Ozdem
Type 2 Diabetes Mellitus (T2DM) increases the risk of cardiovascular diseases. Therefore, elucidation of the cardiovascular effects of antidiabetics is crucial. Incretin-based therapies are increasingly used for T2DM treatment as monotherapy and in combination. We aimed to study the effects of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and sitagliptin on beating rates in isolated atria from diabetic rats. The chronotropic responses to GLP-1 RAs and sitagliptin as monotherapy and in combinations with metformin, pioglitazone, and glimepiride in isolated atria from control and diabetic rats were determined...
March 25, 2024: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/38540237/different-coactivator-recruitment-to-human-ppar%C3%AE-%C3%AE-%C3%AE-ligand-binding-domains-by-eight-ppar-agonists-to-treat-nonalcoholic-fatty-liver-disease
#15
JOURNAL ARTICLE
Shotaro Kamata, Akihiro Honda, Nonoka Kashiwagi, Ayumi Shimamura, Sayaka Yashiro, Yuna Komori, Aoi Hosoda, Noriyuki Akahoshi, Isao Ishii
Three peroxisome proliferator-activated receptor subtypes, PPARα, PPAR(ß/)δ, and PPARγ, exert ligand-dependent transcriptional control in concert with retinoid X receptors (RXRs) on various gene sets harboring PPAR response elements (PPREs) in their promoter regions. Ligand-bound PPAR/RXR complexes do not directly regulate transcription; instead, they recruit multiprotein coactivator complexes to specific genomic regulatory loci to cooperatively activate gene transcription. Several coactivators are expressed in a single cell; however, a ligand-bound PPAR can be associated with only one coactivator through a consensus LXXLL motif...
March 11, 2024: Biomedicines
https://read.qxmd.com/read/38538694/association-of-anti-diabetic-drugs-and-covid-19-outcomes-in-patients-with-diabetes-mellitus-type-2-and-cardiomyopathy
#16
JOURNAL ARTICLE
Jelena Dimnjaković, Tamara Buble, Pero Ivanko, Ivan Pristaš, Ognjen Brborović, Hana Brborović
There is a scarcity of information on the population with diabetes mellitus type 2 and cardiomyopathy (PDMC) in COVID-19, especially on the association between anti-diabetic medications and COVID-19 outcomes. Study is designed as a retrospective cohort analysis covering 2020 and 2021. Data from National Diabetes Registry (CroDiab) were linked to hospital data, primary healthcare data, the SARS-CoV-2 vaccination database, and the SARS-CoV-2 test results database. Study outcomes were cumulative incidence of SARS-CoV-2 positivity, COVID-19 hospitalizations, and COVID-19 deaths...
March 27, 2024: Scientific Reports
https://read.qxmd.com/read/38533289/screening-of-individuals-with-type-2-diabetes-on-anti-diabetic-agents-for-probable-hypoglycaemia-using-the-stanford-hypoglycemia-questionnaire-shq-in-outpatient-settings-a-cross-sectional-study-from-outpatient-diabetes-care-centres-in-north-india
#17
JOURNAL ARTICLE
Rajiv Awasthi, Arun K Pande, Kumar P Chandra, Vivek Agarwal, Mukulesh Gupta, Ajoy Tewari, Nitin Gupta, Santosh Chaubey, Sandeep Chaudhary, Sajid Ansari, Dinesh Kumar
INTRODUCTION: The study was aimed at identifying the incidence of unreported probable hypoglycaemia in individuals with type 2 diabetes (T2DM) on anti-diabetic medications, using the screening Stanford Hypoglycemia Questionnaire (SHQ) in real-world situations. METHODS: It was a multicentre cross-sectional study on consecutive individuals attending 10 diabetes care centres in Lucknow, Uttar Pradesh, India. The inclusion criteria were as follows: known individuals with T2DM, literate, age greater than or equal to 18 years, on at least one anti-diabetic agent for more than a month and not engaged in regular self-monitoring of blood glucose (SMBG)...
2024: Indian Journal of Endocrinology and Metabolism
https://read.qxmd.com/read/38511769/upregulation-of-pgc-1%C3%AE-expression-by-pioglitazone-mediates-prevention-of-sepsis-induced-acute-lung-injury
#18
JOURNAL ARTICLE
Jing Tang, Wenzhu Dong, Dan Wang, Qin Deng, Honggang Guo, Guibao Xiao
The imbalance between pro-inflammatory M1 and anti-inflammatory M2 macrophages plays a critical role in the pathogenesis of sepsis-induced acute lung injury (ALI). Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) may modulate macrophage polarization toward the M2 phenotype by altering mitochondrial activity. This study aimed to investigate the role of the PGC-1α agonist pioglitazone (PGZ) in modulating sepsis-induced ALI. A mouse model of sepsis-induced ALI was established using cecal ligation and puncture (CLP)...
2024: Brazilian Journal of Medical and Biological Research
https://read.qxmd.com/read/38499395/pioglitazone-reverses-alcohol-induced-alterations-in-alveolar-macrophage-mitochondrial-phenotype
#19
JOURNAL ARTICLE
Kathryn M Crotty, Shayaan A Kabir, Sarah S Chang, Ashish J Mehta, Samantha M Yeligar
BACKGROUND: People with alcohol use disorder (AUD) have an increased risk of developing pneumonia and pulmonary diseases. Alveolar macrophages (AMs) are immune cells of the lower respiratory tract that are necessary for clearance of pathogens. However, alcohol causes AM oxidative stress, mitochondrial damage and dysfunction, and diminished phagocytic capacity, leading to lung injury and immune suppression. METHODS: AMs were isolated by bronchoalveolar lavage from people with AUD and male and female C57BL/6J mice given chronic ethanol (20% w/v, 12 weeks) in drinking water...
March 18, 2024: Alcohol Clin Exp Res (Hoboken)
https://read.qxmd.com/read/38485342/jtt-654-an-11-beta-hydroxysteroid-dehydrogenase-type-1-inhibitor-improves-hypertension-and-diabetic-kidney-injury-by-suppressing-angiotensinogen-production
#20
JOURNAL ARTICLE
Shiro Heitaku, Tomohiko Sasase, Tomohiro Sotani, Mimi Maki, Takashi Kawai, Hisayo Morinaga, Jun Nishiu
11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) plays an important role in regulating the expression of glucocorticoid actions in target tissues. Overexpression of 11β-HSD1 in mouse adipose tissue causes a metabolic syndrome-like phenotype, leading to hypertension. Although, many 11β-HSD1 inhibitors have been studied, few have shown a clear ameliorative effect against hypertension. We investigated whether JTT-654, a novel 11β-HSD1 inhibitor, ameliorated hypertension and elucidated the underlying mechanisms...
April 2024: Journal of Pharmacological Sciences
keyword
keyword
42459
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.